Raymond James Lowers Johnson & Johnson (NYSE:JNJ) Price Target to $165.00

Johnson & Johnson (NYSE:JNJ) had its target price lowered by Raymond James from $170.00 to $165.00 in a report issued on Thursday morning,Benzinga reports. Raymond James currently has an outperform rating on the stock.

Several other brokerages have also weighed in on JNJ. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 17th. Bank of America cut their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $170.06.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE:JNJ opened at $146.76 on Thursday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The stock has a market cap of $353.34 billion, a P/E ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.51. The business has a fifty day moving average of $147.85 and a two-hundred day moving average of $155.99. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, research analysts expect that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 74.59%.

Insider Buying and Selling

In other news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently modified their holdings of the company. IFS Advisors LLC raised its stake in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its stake in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the last quarter. Finally, Activest Wealth Management acquired a new position in Johnson & Johnson in the third quarter valued at approximately $40,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.